MARKET

KDMN

KDMN

Kadmon Holdings
NYSE

Real-time Quotes | Nasdaq Last Sale

4.250
+0.430
+11.26%
After Hours: 4.250 0 0.00% 16:00 08/07 EDT
OPEN
3.900
PREV CLOSE
3.820
HIGH
4.250
LOW
3.830
VOLUME
2.78M
TURNOVER
--
52 WEEK HIGH
5.50
52 WEEK LOW
2.040
MARKET CAP
680.11M
P/E (TTM)
-6.0958
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average KDMN stock price target is 12.60 with a high estimate of 25.00 and a low estimate of 8.00.

EPS

KDMN News

More
Kadmon EPS misses by $0.03, misses on revenue
Kadmon (NYSE:KDMN): Q2 GAAP EPS of -$0.17 misses by $0.03. Revenue of $0.45M (+95.7% Y/Y) misses by $0.06M. Shares +2.09% AH. Press Release
seekingalpha · 1d ago
Kadmon Granted US Patent For 'Treatment of infectious diseases with glucose uptake inhibitors'
https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=10729691.PN.&OS=PN/10729691&RS=PN/10729691
Benzinga · 4d ago
Did Hedge Funds Make The Right Call On Kadmon Holdings, Inc. (KDMN) ?
The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F filings show the funds' and investors' portfolio positions as of
Insider Monkey · 07/12 23:39
Missed the biotech breakout? These stocks in the industry are still set to run, MKM says
Biotechnology stocks have ripped higher in 2020 and some investors might have missed their chance to capitalize on the surge.
CNBC.com · 07/03 12:37
Liminal BioSciences up big on start of convalescent plasma collection
Seeking Alpha - Article · 07/01 19:19
Kadmon Doses First Patient In Phase 1 Clinical Trial Of KD033, An Anti-PD-L1/IL-15 Fusion Protein, In Adults With Metastatic Or Locally Advanced Solid Tumors
NEW YORK, NY / ACCESSWIRE / June 23, 2020 / Kadmon Holdings, Inc. (NYSE:KDMN) today announced that the first patient has been dosed in a Phase 1 clinical trial evaluating KD033, an anti-PD-L1/IL-15 fusion protein,
Benzinga · 06/23 12:03
Hedge Funds Arent Done Buying Kadmon Holdings, Inc. (KDMN)
Insider Monkey · 06/08 07:22
3 Strong Buy Biotech Stocks Under $5 With Major Catalysts Approaching
TipRanks · 06/01 14:56

Industry

Pharmaceuticals
+0.19%
Pharmaceuticals & Medical Research
+0.08%

Hot Stocks

Symbol
Price
%Change

About KDMN

Kadmon Holdings, Inc. is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases. Its product pipeline consists of KD025, Tesevatinib and KD034. The Company's other products include Ribasphere RibaPak, Ribasphere, Qsymia, Tetrabenazine and Valganciclovir. KD025 is an orally available, selective small molecule inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2), a molecular target in multiple autoimmune, fibrotic and neurodegenerative diseases. Tesevatinib is an oral tyrosine kinase inhibitor (TKI) designed to block key molecular drivers of tumor growth, metastases and drug resistance. KD034 is the Company's portfolio of enhanced formulations of trientine hydrochloride for the treatment of Wilson's disease.
More

Webull offers kinds of Kadmon Holdings Inc stock information, including NYSE:KDMN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KDMN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading KDMN stock methods without spending real money on the virtual paper trading platform.